FDA clears RapidAI's pulmonary embolism software

By AuntMinnie.com staff writers

February 22, 2023 -- The U.S. Food and Drug Administration (FDA) has cleared RapidAI's Rapid RV/LV, a program that calculates heart metrics associated with pulmonary embolism.

The software assesses the ratio between the right ventricle and the left ventricle, a key indicator of pulmonary embolism severity. Key benefits of Rapid RV/LV include identifying patients with possible right heart strain, reducing time to diagnosis, and reducing variability in RV/LV measurements, according to the company.

Copyright © 2023 AuntMinnie.com

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking